The Beneficial Effects of QIAPI 1® against Pentavalent Arsenic-Induced Lung Toxicity : A Hypothetical Model for SARS CoV2-I nduced Lung Toxicity
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Exposure to environmental toxicants such as Arsenic (As) can result in As-induced alterations in immune regulators. Consequently, people who are more prone to viral infections like influenza A or B, H1N1, SARS CoV (Severe Acute Respiratory Syndrome Coronavirus), and SARS CoV2 may develop a susceptibility to immune responses in their lungs because our previous reports delineated the ability of QIAPI 1®, a melanin precursor, to dissociate water molecules with simultaneous therapeutic efficacy against central nervous system (CNS) diseases, retinopathy, and As-induced renal toxicity. Considering the commonalitie of lung pathology of SARS CoV and As-induced toxicity, the aim of this study is to decipher the efficacy of QIAPI 1® against pentavalent As-induced lung toxicity by examining the pulmonary pathology. Hematoxylin & Eosin (H&E) staining was used for ascertaining the lung pathology in Wistar rat models. Animals were divided into 3 groups: control group, group treated with pentavalent As, and a group treated with pentavalent As and QIAPI 1®. There were no significant changes in lung histopathology in the control group as indicated by intact morphology. The As-treated group revealed damage to the histoarchitecture with pulmonary edema, interstitial fibrosis, diffuse alveolar damage, Bronchiolitis obliterans organizing pneumonia (BOOP)-lesions, formation of hyaline membrane, multinucleated giant pneumocytes, atypical pneumocytes, inflammatory cell infiltration, and interstitial edema. The group treated with As and QIAPI 1® significantly associated with mitigated histological signs of lung inflammation induced by Arsenic. Therefore, QIAPI 1® can be recommended as antagonistic to Asinduced lung toxicity. In conclusion, this model could be preferred as a hypothetical model to examine the efficacy of QIAPI 1® in SARS CoV2-induced pulmonary damage. Future studies are warranted to delineate the efficacy of QIAPI 1® against SARS CoV and SARS CoV2 lung pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 23(2022), 2 vom: 09., Seite 307-315 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herrera, Arturo Solís [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alveoli |
|---|
| Anmerkungen: |
Date Completed 19.01.2022 Date Revised 19.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389201022666210412142230 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324007566 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324007566 | ||
| 003 | DE-627 | ||
| 005 | 20231225185408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389201022666210412142230 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM324007566 | ||
| 035 | |a (NLM)33845734 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Herrera, Arturo Solís |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Beneficial Effects of QIAPI 1® against Pentavalent Arsenic-Induced Lung Toxicity |b A Hypothetical Model for SARS CoV2-I nduced Lung Toxicity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2022 | ||
| 500 | |a Date Revised 19.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Exposure to environmental toxicants such as Arsenic (As) can result in As-induced alterations in immune regulators. Consequently, people who are more prone to viral infections like influenza A or B, H1N1, SARS CoV (Severe Acute Respiratory Syndrome Coronavirus), and SARS CoV2 may develop a susceptibility to immune responses in their lungs because our previous reports delineated the ability of QIAPI 1®, a melanin precursor, to dissociate water molecules with simultaneous therapeutic efficacy against central nervous system (CNS) diseases, retinopathy, and As-induced renal toxicity. Considering the commonalitie of lung pathology of SARS CoV and As-induced toxicity, the aim of this study is to decipher the efficacy of QIAPI 1® against pentavalent As-induced lung toxicity by examining the pulmonary pathology. Hematoxylin & Eosin (H&E) staining was used for ascertaining the lung pathology in Wistar rat models. Animals were divided into 3 groups: control group, group treated with pentavalent As, and a group treated with pentavalent As and QIAPI 1®. There were no significant changes in lung histopathology in the control group as indicated by intact morphology. The As-treated group revealed damage to the histoarchitecture with pulmonary edema, interstitial fibrosis, diffuse alveolar damage, Bronchiolitis obliterans organizing pneumonia (BOOP)-lesions, formation of hyaline membrane, multinucleated giant pneumocytes, atypical pneumocytes, inflammatory cell infiltration, and interstitial edema. The group treated with As and QIAPI 1® significantly associated with mitigated histological signs of lung inflammation induced by Arsenic. Therefore, QIAPI 1® can be recommended as antagonistic to Asinduced lung toxicity. In conclusion, this model could be preferred as a hypothetical model to examine the efficacy of QIAPI 1® in SARS CoV2-induced pulmonary damage. Future studies are warranted to delineate the efficacy of QIAPI 1® against SARS CoV and SARS CoV2 lung pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a QIAPI1® | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a alveoli | |
| 650 | 4 | |a arsenic | |
| 650 | 4 | |a fibrosis. | |
| 650 | 4 | |a lung toxicity | |
| 650 | 7 | |a Arsenic |2 NLM | |
| 650 | 7 | |a N712M78A8G |2 NLM | |
| 700 | 1 | |a Beeraka, Narasimha M |e verfasserin |4 aut | |
| 700 | 1 | |a Sinelnikov, Mikhail Y |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolenko, Vladimir N |e verfasserin |4 aut | |
| 700 | 1 | |a Giller, Dimitry B |e verfasserin |4 aut | |
| 700 | 1 | |a Solis, Luis Fernando Torres |e verfasserin |4 aut | |
| 700 | 1 | |a Mikhaleva, Liudmila M |e verfasserin |4 aut | |
| 700 | 1 | |a Somasundaram, Siva G |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkland, Cecil E |e verfasserin |4 aut | |
| 700 | 1 | |a Aliev, Gjumrakch |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g 23(2022), 2 vom: 09., Seite 307-315 |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g day:09 |g pages:307-315 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389201022666210412142230 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 2 |b 09 |h 307-315 | ||